Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems
Abstract Parkinson’s Disease (PD) involves degeneration of dopamine-producing neurons, mitochondrial dysfunction, alpha-synuclein aggregation, neuroinflammation, and gut-brain axis disturbances. Despite the availability of pharmacological treatments, these interventions fail to prevent disease progr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-025-01081-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226515642843136 |
|---|---|
| author | Jude Majed Lababidi Hassan Mohamed El-Said Azzazy |
| author_facet | Jude Majed Lababidi Hassan Mohamed El-Said Azzazy |
| author_sort | Jude Majed Lababidi |
| collection | DOAJ |
| description | Abstract Parkinson’s Disease (PD) involves degeneration of dopamine-producing neurons, mitochondrial dysfunction, alpha-synuclein aggregation, neuroinflammation, and gut-brain axis disturbances. Despite the availability of pharmacological treatments, these interventions fail to prevent disease progression due to their limited ability to penetrate the blood-brain barrier (BBB) and systemic side effects. Phytochemicals, known for their antioxidant and neuroprotective properties, offer a complementary approach to PD treatment. However, their therapeutic potential is limited by rapid metabolism and poor bioavailability. Several nanoparticles were suggested to enhance the stability and bioavailability of therapeutic agents while enabling controlled release and improved BBB penetration. This review is focused on the use of poly (lactic-co-glycolic acid) (PLGA)-based nanosystem as advanced drug delivery carriers for PD due to its versatility, safety, biodegradability, and extensive studies which evaluated the use of PLGA for drug delivery. It also evaluates their use for encapsulating pharmacological drugs such as dopamine agonists, dopamine precursors, COMT inhibitors, and MAO-B inhibitors, addressing the limitations of conventional therapies. Additionally, the review highlights the utility of PLGA nanoparticles in delivering phytochemicals with neuroprotective effects such as polyphenols, flavonoids, and coumarins to overcome challenges associated with their solubility and stability and ultimately enhance their activities for managing PD. |
| format | Article |
| id | doaj-art-a46b58f1ac4b407f9e5d41a542e5f9fb |
| institution | Kabale University |
| issn | 2373-8057 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj-art-a46b58f1ac4b407f9e5d41a542e5f9fb2025-08-24T11:14:44ZengNature Portfolionpj Parkinson's Disease2373-80572025-08-0111112610.1038/s41531-025-01081-1Revamping Parkinson’s disease therapy using PLGA-based drug delivery systemsJude Majed Lababidi0Hassan Mohamed El-Said Azzazy1Department of Chemistry, School of Sciences & Engineering, The American University in Cairo, AUC AvenueDepartment of Chemistry, School of Sciences & Engineering, The American University in Cairo, AUC AvenueAbstract Parkinson’s Disease (PD) involves degeneration of dopamine-producing neurons, mitochondrial dysfunction, alpha-synuclein aggregation, neuroinflammation, and gut-brain axis disturbances. Despite the availability of pharmacological treatments, these interventions fail to prevent disease progression due to their limited ability to penetrate the blood-brain barrier (BBB) and systemic side effects. Phytochemicals, known for their antioxidant and neuroprotective properties, offer a complementary approach to PD treatment. However, their therapeutic potential is limited by rapid metabolism and poor bioavailability. Several nanoparticles were suggested to enhance the stability and bioavailability of therapeutic agents while enabling controlled release and improved BBB penetration. This review is focused on the use of poly (lactic-co-glycolic acid) (PLGA)-based nanosystem as advanced drug delivery carriers for PD due to its versatility, safety, biodegradability, and extensive studies which evaluated the use of PLGA for drug delivery. It also evaluates their use for encapsulating pharmacological drugs such as dopamine agonists, dopamine precursors, COMT inhibitors, and MAO-B inhibitors, addressing the limitations of conventional therapies. Additionally, the review highlights the utility of PLGA nanoparticles in delivering phytochemicals with neuroprotective effects such as polyphenols, flavonoids, and coumarins to overcome challenges associated with their solubility and stability and ultimately enhance their activities for managing PD.https://doi.org/10.1038/s41531-025-01081-1 |
| spellingShingle | Jude Majed Lababidi Hassan Mohamed El-Said Azzazy Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems npj Parkinson's Disease |
| title | Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems |
| title_full | Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems |
| title_fullStr | Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems |
| title_full_unstemmed | Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems |
| title_short | Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems |
| title_sort | revamping parkinson s disease therapy using plga based drug delivery systems |
| url | https://doi.org/10.1038/s41531-025-01081-1 |
| work_keys_str_mv | AT judemajedlababidi revampingparkinsonsdiseasetherapyusingplgabaseddrugdeliverysystems AT hassanmohamedelsaidazzazy revampingparkinsonsdiseasetherapyusingplgabaseddrugdeliverysystems |